Prognostic impact of targetable driver alterations in resected early-stage lung cancer
Open Access
- 1 November 2024
- journal article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (11) , 3096-3105
Abstract
Background: Apart from ALK fusions and the common EGFR mutations, targetable molecular alterations are irrelevant for adjuvant treatment decision making in early-stage non-small cell lung cancer (NSCLC). This retrospective analysis aimed to investigate if there is a difference in recurrence-free survival in stage I–III NSCLC harboring druggable molecular alterations compared to subtypes without targetable molecular alterations. Methods: All consecutive patients who underwent surgery with curative intent for NSCLC (stage I–III) with targetable mutations between January 2015 and December 2020 at three Austrian institutions were identified and compared with tumors without targetable molecular alterations. Tumors with the EGFR-mutated subtype were excluded due to already existing results from prospective trials. Results: One hundred and sixty subjects had tumors with molecular alterations and 355 subjects served as control cohort. There was a higher prevalence of female sex (PKRAS G12C mutation (n=92), ALK fusions (n=21), and the BRAF V600E mutation (n=15). The 1-, 3- and 5-year cumulative incidence of recurrence estimates were 16%, 38% and 46% in patients without molecular alterations and 16%, 38% and 48% in patients with the KRAS G12C mutation and 12%, 33% and 55% in patients with other molecular alterations, respectively (P=0.89). Univariable predictors of an increased recurrence risk were higher tumor stage (PKRAS G12C mutation and P=0.43 for any other molecular alteration). Conclusions: NSCLC patients with resected tumors that harbor molecular alterations have the same recurrence risk as patients with tumors without molecular alterations if treated with surgery plus chemotherapy when indicated.Keywords
This publication has 27 references indexed in Scilit:
- Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung CancerJAMA, 2019
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- Genomic alterations in lung adenocarcinomaThe Lancet Oncology, 2015
- KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung AdenocarcinomaJournal of Thoracic Oncology, 2014
- ROS1 expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 casesHistopathology, 2014
- Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerAnnals of Oncology, 2012
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Estimation of failure probabilities in the presence of competing risks: new representations of old estimatorsStatistics in Medicine, 1999
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996